Eli Lilly delays FDA filing for next-generation weight-loss drug retatrutide
Eli Lilly is planning a Q1 2027 FDA application for retatrutide following new data on weight loss and A1C improvements.
Velocity timeline
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
Eli Lilly has announced plans to file its FDA application for the next-generation obesity drug retatrutide in the first quarter of 2027. This timeline follows reports that the filing has been delayed.
Coverage from Reuters, Drug Topics, Everyday Health, and NewsNation emphasizes positive trial results. Retatrutide has demonstrated A1C improvements and helped adults with diabetes or heart disease lose up to 20 percent of their weight.
Future developments depend on the upcoming Q1 2027 FDA application process and the continued release of next-generation obesity drug data.
Synthesized by Newsylist from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated just now.
Quick answers
When does Eli Lilly plan to apply to the FDA for retatrutide?
The company plans to submit the application in the first quarter of 2027.
What results have been reported in retatrutide trials?
Study findings indicate A1C improvements and weight loss of up to 20 percent in adults with heart disease or diabetes.
Which outlets are reporting on this delay and data?
Coverage includes reports from Reuters, NewsNation, Drug Topics, and Everyday Health.
Coverage (4)
- Lilly announces more next-gen obesity drug data, plans Q1 2027 FDA application Reuters · 11h ago
- Retatrutide Delivers Weight Loss, A1C Improvements in Additional Trials Drug Topics · 20h ago
- Retatrutide Helped Adults With Diabetes or Heart Disease Lose Up to 20 Percent of Their Weight, Study Finds Everyday Health · 2d ago
- Eli Lilly delays FDA filing for next-generation weight-loss drug retatrutide NewsNation · 2d ago broke it first
People, places & organizations
Topics
Related trends
Ahead of hearing, FDA questions the efficacy of Capricor’s Duchenne drug
Capricor Therapeutics shares have plunged after FDA staff raised concerns regarding the efficacy and data of its Duchenne heart disease therapy.
Compounded GLP-1 drugs creating concern among doctors and FDA
Doctors and the FDA are warning against the use of compounded GLP-1 weight-loss drugs due to potential health risks and troubling study findings.
FDA Approves Centanafadine for ADHD in Children, Adolescents, and Adults
The FDA has approved Otsuka's Simtriyo (centanafadine), the first new-class ADHD medication for pediatric and adult patients in decades.
Cyclospora outbreak has many changing eating habits, CBS News poll finds; mixed and partisan confidence in FDA
A Cyclospora outbreak is shifting consumer eating habits and fueling a surge in demand for local produce and home-grown greens.
Taylor Farms CEO breaks silence over explosive diarrhea outbreak as class-action lawsuit filed
Taylor Farms faces a class-action lawsuit and operational shutdowns following a cyclosporiasis outbreak linked to its products.
Brooklyn Roasting Company recalls cold brew sold in New York and New Jersey over botulism risk
Brooklyn Roasting Company is recalling over 3,000 gallons of cold brew concentrate sold in New York and New Jersey due to a potential botulism risk.